• CRO M&A Market in 2020 (So Far)

    There haven’t been many deals targeting contract research organizations (CRO) in 2020, especially compared to previous years, which makes sense. Life science companies are all slowing down clinical trials (COVID-19 vaccine research excluded) to adhere to social distancing guidelines, meaning CRO services are just not in as high demand. For... Read More »
  • Ophthalmology Groups Are Still Selling

    Despite the effects of COVID-19 on physician groups, investors are still acquiring ophthalmology groups, especially in the third quarter, according to DSO. Just last week, EyeSouth Partners acquired Retina Associates of Middle Georgia (RAMG) for an undisclosed sum. Based in Macon, Georgia, RAMG provides treatment for the retina, macula, and... Read More »
  • Hospice M&A Activity Surges in 2020

    Despite the volatile market conditions for healthcare M&A, hospice targets have remained a remarkably consistent draw for investors, according to data captured in DSO. In the second quarter of 2020, 70% of HH&H transactions were for hospice specific targets, or targets that provided only hospice services, instead of a mix of hospice and... Read More »
  • Teladoc Health and Livongo Health Merge

    The virtual care giant Teladoc Health, Inc. (NYSE: TDOC) is having a wild year. The company’s second-quarter earnings reports showed Teladoc’s year-over-year revenues surged by 85% to $241 million, and its total telehealth visits rose to 2.8 million, a year-over-year increase of 203%, all thanks to the effects of COVD-19. And now,... Read More »
  • Health Care M&A Deals, August 7, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week was... Read More »
Celgene Sells Otezla to Advance its Sale to Bristol-Myers Squibb

Celgene Sells Otezla to Advance its Sale to Bristol-Myers Squibb

Amgen (NASDAQ: AMGN) has agreed to take Otezla (apremilast) off of Celgene Corporation’s (NASDAQ: CELG) hands. The Federal Trade Commission ruled the drug had to be divested due to concerns over competition with Bristol-Myers Squibb’s (NYSE: BMY) pipeline. Bristol-Myers announced it was buying Celgene last January for $74 billion. In this deal, Amgen gains the worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities. Sales of Otezla in 2018 were $1.6 billion and the drug has intellectual property exclusivity in the United States at least through 2028. Amgen will pay $13.4 billion in cash,... Read More »
Healthcare Dollar Volume Exploded in January

Healthcare Dollar Volume Exploded in January

Dollar volume for healthcare deals announced in January was ridiculous, topping $90 billion. We don’t see figures like that in most quarters. The outsized total results from a single deal, of course. Bristol-Myers Squibb’s (NYSE: BMY) $74 billion acquisition of Celgene Corp. (NASDAQ: CELG) made up 81% of the month’s total. Suffice it to say we won’t see many (or any) more months like this. The Hospital sector made a strong contribution, nearly $6 billion. The biggest deal wasn’t a domestic one, however. Australia’s second largest private hospital network, Healthscope Ltd. (ASX: HSO), was acquired by Brookfield Business Partners LP (NYSE: BBU) for approximately $4.1 billion. Two REITs are... Read More »
Biotechnology Gets the Usual January Boost

Biotechnology Gets the Usual January Boost

The Biotechnology sector roared to life in 2017, posting a record 209 transactions. That’s 20% higher than the 174 deals announced in 2016. The previous record for the sector was set in 2009, with 193 transactions announced in the space. Spending for those 209 deals in 2017 didn’t set new records, but did post an impressive $54.5 billion in disclosed prices. That’s 283% higher than the $18.6 billion recorded in all of 2016, but not close to the secctor’s annual spending record of $93.9 billion, set in 2008. Every January, the Biotechnology Showcase is held in San Francisco, concurrent with the J.P. Morgan Healthcare conference. And every January, this sector sees... Read More »